Every material Form 8-K ResMed has filed with the SEC since August 16, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ResMed Inc. reported first-quarter fiscal year 2027 revenue of $1.4 billion, representing a 6% increase compared to the prior-year period. GAAP diluted earnings per share rose 23% to $2.92, while the board declared a quarterly cash dividend of $0.66 per share.
Q1 revenue increased 6% to $1.4 billion, or 7% on a core constant currency basis.
GAAP diluted earnings per share grew 23% to $2.92, and non-GAAP diluted EPS rose 14% to $2.91.
The board of directors declared a quarterly cash dividend of $0.66 per share, payable on December 17, 2026, with a record date of November 12, 2026.
The company returned more than $1.0 billion to shareholders through share repurchases and dividends during the quarter.
ResMed dismissed KPMG as its independent auditor on August 13, 2026, and appointed PricewaterhouseCoopers for the fiscal year ending June 30, 2027, subject to PwC's client acceptance procedures. The filing also reports that director Ron Taylor will not stand for reelection and will retire at the November 18, 2026 annual meeting, with Carol Burt named lead director effective November 15, 2026.
KPMG's reports on the fiscal 2026 and 2025 financial statements contained no adverse opinion, disclaimer, or qualification, and the filing reports no disagreements or reportable events.
PwC appointed on August 13, 2026, following a competitive review by the Audit Committee, subject to completion of its standard client acceptance procedures.
Ron Taylor, a director since 2005 and lead director since 2013, is retiring at the 2026 Annual Meeting on November 18, 2026, and his retirement is not due to any disagreement with the company.
Carol Burt, a Board member since 2013 who chairs the Nominating and Governance Committee, becomes lead director on November 15, 2026.
ResMed reported fiscal fourth-quarter 2026 revenue of $1.46 billion, up 9% from a year earlier, and GAAP diluted earnings per share of $2.64, up 2%. Its board also declared a 10% dividend increase to $0.66 per share, with an ex-dividend date of August 19, 2026, which matters to shareholders receiving the payout.
Q4 revenue $1.46 billion, up 9% (8% in constant currency); GAAP diluted EPS $2.64, up 2%
Non-GAAP diluted EPS $2.95, up 16%; GAAP results include $42 million in Astral field safety notification expenses
Quarterly dividend of $0.66 per share, record date August 20, 2026, payable September 24, 2026
Company guides to more than $1.85 billion returned to shareholders through buybacks and dividends in fiscal 2027
ResMed agreed on June 30, 2026 to sell its MatrixCare business to private equity firm Frazier Healthcare Partners for $490 million in cash, subject to closing adjustments. The company plans to use the proceeds to return capital to shareholders, including an accelerated share repurchase, and for general corporate purposes. The filing reiterates ResMed's fiscal 2026 outlook and says the full fiscal 2027 outlook will be given on August 6, 2026.
Buyer is Frazier Healthcare Partners; price is $490 million all-cash, subject to certain closing adjustments.
Deal is expected to close in the first quarter of fiscal 2027, subject to regulatory approvals and customary conditions.
MatrixCare had approximately $220 million of revenue and $55 million of non-GAAP operating profit in fiscal 2026, based on preliminary results.
Recently completed Noctrix acquisition is expected to add about $30 million of fiscal 2027 revenue and reduce non-GAAP diluted EPS by about $0.20.
ResMed said CFO Brett Sandercock will retire, with Aaron Bloomer, formerly CFO of Exact Sciences, taking over as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer effective May 4, 2026. The company said the retirement was not the result of any disagreement on operations, policies or practices, and it reiterated its fiscal 2026 outlook alongside the announcement.
Sandercock serves as CFO until May 4, 2026, then as Special Advisor to Chairman and CEO Mick Farrell through December 31, 2026, and in a consulting role through December 31, 2027.
Bloomer, age 40, receives a $725,000 base salary, a $150,000 sign-on bonus and a $3,300,000 long-term performance equity grant when he joins.
Bloomer is also eligible for a $3,300,000 equity grant in November 2026 for fiscal year 2027.
ResMed reiterated fiscal 2026 outlook, including gross margin of 62-63%.
ResMed reported results for the quarter ended March 31, 2026, with revenue up 11% to $1.43 billion and GAAP diluted EPS of $2.74, up from $2.48, while non-GAAP diluted EPS rose 21% to $2.86. The company also declared a quarterly cash dividend of $0.60 per share, with a record date of May 14, 2026 and payment on June 18, 2026.
Revenue was $1,431.4 million, up 11% reported and 8% on a constant currency basis; GAAP gross margin rose 290 basis points to 62.2%.
GAAP net income was $398.7 million; non-GAAP net income rose 20% to $417.2 million.
Operating cash flow was $554 million; the company paid $87 million in dividends and repurchased shares for $175 million in the quarter.
Quarterly dividend of $0.60 per share: ex-dividend date May 13, 2026; record date May 14, 2026; payable June 18, 2026.
ResMed reported results for the quarter ended December 31, 2025, with revenue up 11% to $1.4 billion and GAAP diluted earnings per share up 15% to $2.68. The company also declared a quarterly cash dividend of $0.60 per share, with a record date of February 12, 2026, and payment on March 19, 2026.
Revenue of $1,422.8 million, up 11% (9% in constant currency) from $1,282.1 million a year earlier
GAAP diluted EPS of $2.68 versus $2.34; non-GAAP diluted EPS of $2.81 versus $2.43
Operating cash flow of $340 million; $6 million of restructuring charges recorded in the quarter
Quarterly dividend of $0.60 per share; ex-dividend date February 11, 2026
At its November 19, 2025 annual meeting, ResMed stockholders approved amendments adding 2,400,000 shares to the 2009 Incentive Award Plan and 3,000,000 shares to the 2018 Employee Stock Purchase Plan, and elected eleven directors. Director Richard Sulpizio did not seek re-election, and the board reduced its size from twelve seats to eleven. The added shares increase the pool available for employee equity awards and stock purchases.
2009 Plan amendment: 2,400,000 additional shares, elimination of the fixed term, and authorization of incentive stock options
ESPP amendment: 3,000,000 additional shares, elimination of the fixed term, and tax-qualified options under Section 423
Say-on-pay advisory vote: 98,435,762 for, 11,004,916 against, 236,395 abstain
KPMG LLP ratified as independent auditor for fiscal year ending June 30, 2026: 103,397,962 for, 10,908,581 against
ResMed reported first-quarter fiscal 2026 results with revenue up 9% to $1.3 billion and diluted earnings per share of $2.37, up 12% from $2.11 a year earlier. The company also declared a quarterly dividend of $0.60 per share, payable December 18, 2025, which is the figure shareholders will receive per common share.
Revenue rose 9% to $1.3 billion ($1,335.6 million), or 8% on a constant currency basis.
Diluted EPS was $2.37 versus $2.11; non-GAAP diluted EPS was $2.55 versus $2.20, up 16%.
Restructuring charges of $16 million were recorded following company-wide workforce planning.
Quarterly cash dividend of $0.60 per share; record date November 13, 2025; ex-dividend date November 12, 2025.
ResMed elected Nicole Mowad-Nassar, senior vice president at AbbVie, to its board effective August 15, 2025. Director Richard Sulpizio, who has served since 2005, will not stand for reelection and will retire at the November 19, 2025 annual meeting. The filing does not describe any financial effect of these board changes.
Nicole Mowad-Nassar elected August 15, 2025, with a term running to the 2025 annual meeting on November 19, 2025; she joins the Compensation and Leadership Development Committee
Mowad-Nassar is SVP at AbbVie and president of specialty and U.S. therapeutics operations, a role held since July 2023
Richard Sulpizio, a director since 2005, will retire at the 2025 annual meeting; the filing says his decision is not due to any disagreement with ResMed
Non-executive director cash retainer increases to $75,000 for fiscal year 2026, as approved by the board in May 2025
ResMed said its chief commercial officer for the residential care software business, Bobby Ghoshal, notified the company on July 28, 2025 that he intends to resign effective August 1, 2025, to become chief operating officer of a software company outside its industry. The filing does not name a successor or describe any financial impact.
Bobby Ghoshal, chief commercial officer of the residential care software business (RCS), gave notice on July 28, 2025.
Resignation is effective August 1, 2025.
He plans to join a software company in a non-competitive industry as chief operating officer.
The filing does not name a replacement or report any financial effect.
ResMed reported fourth-quarter fiscal 2025 results for the quarter ended June 30, 2025, with revenue up 10% to $1.3 billion and diluted earnings per share up 30% to $2.58. The company also declared a quarterly dividend of $0.60 per share, a 13% increase, payable September 18, 2025 to holders of record on August 14, 2025.
Q4 revenue $1,348.0 million, up 10% (9% constant currency); income from operations up 19% to $454.5 million
Q4 diluted EPS $2.58 vs. $1.98 a year earlier; non-GAAP diluted EPS $2.55 vs. $2.08
Full-year revenue $5.1 billion, up 10%; full-year diluted EPS $9.51 vs. $6.92
Quarterly dividend $0.60 per share; ex-dividend date August 13, 2025
ResMed reported results for the quarter ended March 31, 2025, with revenue up 8% to $1.3 billion and diluted EPS of $2.48, up from $2.04 a year earlier. The board also declared a $0.53 per share quarterly dividend, with a May 8, 2025 record date and a June 12, 2025 payment date.
Revenue $1,291.7 million, up 8% (9% constant currency); gross margin 59.3%, up 140 basis points
Income from operations $426.3 million, up 14%; net income $365.0 million, up 21%
Quarterly dividend of $0.53 per share; ex-dividend date May 7, 2025, payable June 12, 2025
Operating cash flow $579 million, including $107 million in IRS tax refunds
ResMed reported fiscal second-quarter 2025 results for the quarter ended December 31, 2024, with revenue up 10% to $1.3 billion and diluted earnings per share of $2.34, up from $1.42. The prior-year quarter included $64.2 million of restructuring charges, which lifts the year-over-year comparison; non-GAAP diluted EPS rose 29% to $2.43. The board also declared a quarterly dividend of $0.53 per share.
Revenue rose 10% to $1.3 billion ($1,282.1 million); gross margin improved 300 basis points to 58.6%.
Diluted EPS was $2.34 versus $1.42; non-GAAP diluted EPS was $2.43 versus $1.88.
Operating cash flow was $309 million; $78 million was paid in dividends and $75 million was spent on share repurchases.
Quarterly dividend of $0.53 per share has a February 13, 2025 record date and is payable March 20, 2025.
ResMed reported fiscal first-quarter 2025 results, with revenue up 11% to $1.2 billion, income from operations up 34%, and diluted earnings per share of $2.11, up 42% from $1.49. The company also declared a quarterly cash dividend of $0.53 per share, with a November 7, 2024 record date and December 12, 2024 payment date.
Revenue rose 11% to $1.2 billion; gross margin improved 420 basis points to 58.6%.
Diluted EPS was $2.11 (GAAP) and $2.20 (non-GAAP), versus $1.49 and $1.64 a year earlier.
Quarterly cash dividend of $0.53 per share; ex-dividend date November 6, 2024, payable December 12, 2024.
Operating cash flow was $326 million; the company repurchased $50 million of stock during the quarter.
ResMed expanded its board of directors to 11 and appointed Christopher DelOrefice, executive vice president and chief financial officer of Becton, Dickinson and Company, as a director on August 15, 2024. He will also serve on the board's audit committee and stand for re-election at the annual meeting on November 21, 2024. The filing reports no financial results or guidance changes tied to this appointment.
Board expanded from its prior size to 11 directors; DelOrefice appointed August 15, 2024 at a regularly scheduled board meeting
DelOrefice has been CFO of Becton, Dickinson and Company since September 2021 and previously held roles at Johnson & Johnson
Appointed to the audit committee; term runs to the 2024 annual meeting on November 21, 2024
He will receive director compensation on a pro rata basis and a standard indemnification agreement with ResMed
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ResMed filing is on SEC EDGAR ↗. 8-K briefs of other companies →